Agilus Diagnostics, India’s largest diagnostic network, has achieved a breakthrough in genomic testing by introducing a 3-day turnaround time (TAT) for myeloid malignancy test results, setting a new benchmark in precision diagnostics.
The genomic testing market in India, valued at $150 million, is rapidly expanding at a projected CAGR of over 15% in the next five years. Advances in genomic testing, particularly in cancer diagnostics, are transforming treatment by enabling targeted therapy and personalized medicine. Agilus Diagnostics’ cutting-edge offerings place it at the forefront of this growth, addressing critical challenges in precision oncology and significantly improving patient outcomes.
Faster Insights, Better Care
As per the press release, Agilus Diagnostics’ Myeloid Genomics Testing provides rapid, detailed insights into 79 genes, including those linked to inherited risks. The test detects key mutations and fusions, enabling tailored treatment plans for conditions such as Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN). Reviewed by expert molecular pathologists, reports include risk assessments and therapy recommendations aligned with international standards.
For broader applications, the Genomic Profiling Precision Assay offers comprehensive analysis for cancers like lung, colon, breast, and melanoma by examining 50 critical genes. Liquid biopsy results are delivered within two days, while tissue sample reports are ready in seven days, ensuring timely and actionable insights for clinicians.
Transforming Patient Care
“Time is one of the biggest challenges in precision oncology,” said Dr. Anand K, Managing Director and CEO of Agilus Diagnostics. “Our 3-day genomic testing initiative not only sets a new industry standard but also transforms patient care by enabling faster diagnoses and treatments.”
Traditional genomic testing for myeloid malignancies often takes up to three weeks, delaying critical clinical decisions. Agilus Diagnostics’ rapid turnaround significantly shortens this timeline, reducing hospital visits and enhancing the overall patient experience.
Driving Global Standards
Agilus Diagnostics is committed to aligning with global standards in personalized medicine through advanced technology, individualized reporting, and expert oversight. Every test result is meticulously analyzed by molecular pathologists, ensuring clinicians receive actionable insights for timely and effective treatment decisions.
“By combining speed, accuracy, and patient-focused care, we aim to provide world-class diagnostic services that empower clinicians and improve patient outcomes,” added Dr. Anand K.
Agilus Diagnostics continues to lead the way in genomic testing innovation, reaffirming its mission to deliver cutting-edge healthcare solutions and establish itself as a trusted name in precision diagnostics.